Results 71 to 80 of about 44,845 (209)

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

BMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed, Hafiz Ghulam Murtaza Saleem, Sajjad Ullah, Shahzad Latif, Shabana, Junaid Jafar, Ahmad Bilal Waqar   +6 more
doaj   +1 more source

Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection [PDF]

, 2014
Sammy Saab, Stuart C. Gordon, H. Park, Mark Sulkowski, Aijaz Ahmed, Zobair M. Younossi   +5 more
openalex   +1 more source

Hepatitis C patients’ self‐reported adherence to treatment with pegylated interferon and ribavirin [PDF]

, 2008
Jeffrey J. Weiss, Laveeza Bhatti, Douglas T. Dieterich, Brian R. Edlin, Dawn Fishbein, Matthew Bidwell Goetz, Kenneth H. Yu, Glenn J. Wagner   +7 more
openalex   +1 more source

Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis

, 2019
Georgiana G Crişu, Florentina Ioniţă‐Radu, Raluca Costache, Daniel Vasile Balaban, Petruţ Nuţă, Victor Stoica, L. Oana Vutcan, Ion Ştefan, Florica Mali Năftănăilă, Mariana Jinga   +9 more
openalex   +1 more source

P226: Turquoise‐III: safety and efficacy of 12‐week ribavirin‐free treatment for patients with HCV genotype 1b and cirrhosis [PDF]

, 2015

openalex   +1 more source

Construction of Label-Free Sensor for Ribavirin Detection Based on Colloidal Crystal Array and Molecular Imprinting

, 2022
Wei Chen, Yi Sun, Lirui Zhang, Min Fu, Kunhua Wang, Meng Gao   +5 more
openalex   +1 more source

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Clinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C, Nachega J, Mills EJ, Druyts E, Cooper CL   +4 more
doaj  

PIN3 COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY WITH PEGINTERFERONALFA2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®) IN PATIENTS WITH CHRONIC C HEPATITIS (CHC)AND PERSISTENTLY NORMAL ALT LEVELS (PNALT)

, 2005
Carlos Rubio‐Terres, Carmen Sanz, KK Patel   +2 more
openalex   +1 more source

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study [PDF]

, 2016
Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J. Dore, Gail Matthews   +11 more
openalex   +1 more source

Post-transplant plasma cell hepatitis in a liver transplant patient treated with pegylated interferon plus ribavirin

, 2013
Miguel Jiménez‐Pérez, Francisco Javier Rando-Muñoz, Rocío González‐Grande, Fernando González-Panizo Tamargo, Jesús de la Cruz Lombardo, J.M. Rodrigo López, Román Manteca González   +6 more
openalex   +2 more sources